Icosavax (ICVX) Stock

Does Icosavax, Inc. (ICVX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Icosavax, Inc. (ICVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Icosavax (NASDAQ: ICVX ) stock is rising higher on Tuesday after announcing a major acquisition deal with AstraZeneca (NASDAQ: AZN ). According to a press release, AstraZeneca is acquiring Icosavax for $15 per share.

The average of price targets set by Wall Street analysts indicates a potential upside of 175.9% in Icosavax, Inc. (ICVX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Icosavax, Inc. (ICVX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Icosavax (ICVX) surges on positive data from the clinical study of IVX-A12, targeting respiratory syncytial virus and human metapneumovirus in older adults.

Icosavax also initiated a $67.8 million stock sale. The biopharmaceutical company's pipeline also includes vaccines to treat influenza and severe acute respiratory syndrome coronavirus.

Icosavax (ICVX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Icosavax, Inc. (ICVX) came out with a quarterly loss of $0.60 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.60 per share a year ago.